MedDataX Logo

ST-2; a Non-invasive Fibrosis Marker for Chronic Hepatitis B

NCT ID: NCT01633554

Last Updated: 2012-07-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

95 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-01-31

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

IL-33 is a recently identified number of the IL-1 family. Hepatic over-expression of IL-33 has been recently linked to liver fibrosis. ST-2 exerts pro-inflammatory effects of IL-33. We aimed to determine ability of ST2 to predict fibrosis in chronic hepatitis B.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

ST-2 is an IL-1 receptor family member and exists in both a membrane-bound isoform and a soluble (sST2) isoform. It has a functional ligand (Interleukin-33) and via ST-2/IL-33 inflammation and immunity is regulated. Hepatic over-expression of IL-33 has been recently linked to liver fibrosis. ST-2 exerts pro-inflammatory effects of IL-33. We aimed to determine ability of ST2 to predict fibrosis in chronic hepatitis B.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sequela of Chronic Liver Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

ST-2, IL-33, prediction, fibrosis, hepatitis B

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chronic Hepatitis B Group

Patients with chronic hepatitis B

No interventions assigned to this group

Cirrhosis

Patients with liver cirrhosis

No interventions assigned to this group

Control Group

Control Group: Healthy Volunteers

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of chronic hepatitis B or liver cirrhosis

Exclusion Criteria

* Accompanying chronic inflammatory disease
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Turkiye Yuksek Ihtisas Education and Research Hospital

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

İsmail Hakkı KALKAN

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Türkiye Yüksek İhtisas Education and research Hospital

Altındağ, Ankara, Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

İsmail H KALKAN, MD

Role: CONTACT

Phone: +90 312 437 67 78

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

İsmail H KALKAN, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IKalkan24190708

Identifier Type: REGISTRY

Identifier Source: secondary_id

24190708

Identifier Type: -

Identifier Source: org_study_id